Multimodal Contrastive Prototype Learning for Resilient Brain Tumor Segmentation With Missing Modalities.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41474992.
- Also identified by DOI 10.1109/JBHI.2025.3649819.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multimodal fusion is an effective solution for holistic brain tumor diagnosis; however, it faces challenges under missing modalities. Traditional multi-encoder architectures can easily capture modality-specific features, while single-encoder architectures readily obtain modality-shared features. The reverse, however, is challenging. In this paper, we propose a two-stage dual-view prototype learning framework to extract the modality-specific feature and the class-specific feature simultaneously. In the first stage, we utilize the Transformer decoder to learn the modality-prototypes that are used to optimize the modality reconstruction task. A masked autoencoder is introduced to generate shared features of incomplete modalities. The learned modality-prototypes that contain modality-specific features are blended with the modality-share features for the reconstruction process. In the second stage, we learn the class-prototypes through the Transformer decoder to generate a segmentation mask through voxel-to-prototype comparison. A masked modality strategy is introduced to handle random modality absence during training. Furthermore, modality-view and class-view contrastive learning strategies are developed to enhance prototype learning. We conduct experiments on BraTS2020 and BraTS2018; the experimental results demonstrate the superior performance of our model under various missing modality scenarios. On BraTS2020, our model achieves DSC improvements of 5.9% for ET, 0.5% for TC, and 0.2% for WT compared to state-of-the-art methods. Notably, in the challenging T1C modality missing scenario, our model achieved clinically significant gains of 9.5% for ET and 1.8% for TC. The code is available at https://github.com/Xiheran/MCPL.